Bendamustine
- Generic Name
- Bendamustine
- Brand Names
- Belrapzo, Bendeka, Treanda, Vivimusta
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21Cl2N3O2
- CAS Number
- 16506-27-7
- Unique Ingredient Identifier
- 9266D9P3PQ
- Background
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
- Indication
Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 60
- Registration Number
- NCT00274963
- Locations
- 🇩🇪
Schwerpunktpraxis fuer Haematologie und Internistische Onkologie, Berlin, Germany
🇩🇪Internistische Gemeinschaftspraxis - Halle, Halle, Germany
🇩🇪Internistische Praxis - Neuss, Neuss, Germany
Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Biological: Rituximab
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2019-05-23
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 195
- Registration Number
- NCT00274989
- Locations
- 🇩🇪
HELIOS Klinikum Bad Saarow, Bad Saarow, Germany
🇩🇪Internistische Praxis - Arnstadt, Arnstadt, Germany
🇩🇪Klinikum Augsburg, Augsburg, Germany
Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- Cephalon
- Target Recruit Count
- 103
- Registration Number
- NCT00139841
- Locations
- 🇺🇸
USC/Norris Cancer Hospital, Los Angeles, California, United States
🇺🇸LSU Health Sciences Center, Feist Weiller Cancer Center, Shreveport, Louisiana, United States
🇺🇸Markey Cancer Center, University of Kentucky Medical Center, Lexington, Kentucky, United States
SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)
- First Posted Date
- 2004-01-22
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- Cephalon
- Target Recruit Count
- 66
- Registration Number
- NCT00076349
- Locations
- 🇺🇸
Beth Israel/Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Oncology and Hematology, Metairie, Louisiana, United States
🇺🇸Georgetown University Medical Center - Lombardi Cancer Center, Washington, District of Columbia, United States
Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma
- Conditions
- Non-Hodgkin's Lymphoma
- First Posted Date
- 2003-10-02
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- Cephalon
- Target Recruit Count
- 72
- Registration Number
- NCT00069758
- Locations
- 🇺🇸
Southwest Regional Cancer Center, Austin, Texas, United States
🇺🇸San Diego Cancer Center, Vista, California, United States
🇨🇦CHA Hopital Enfant-Jesus, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.